Money and resources go to waste when demand creation doesn't align with market access strategy and execution that doesn't result in placement on critical contracts. Conversely, market access efforts are minimized on drugs with little patient demand. Both are hard slams on the see-saw. How are pharmaceutical manufacturers to manage separated value creation and capture teams? Read on.